Acceptance of universal varicella vaccination among Swiss pediatricians and general practitioners who treat pediatric patients.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
06 Jan 2021
Historique:
received: 07 05 2020
accepted: 04 11 2020
entrez: 7 1 2021
pubmed: 8 1 2021
medline: 20 1 2021
Statut: epublish

Résumé

Over the last two decades, several countries have initiated universal varicella vaccination (UVV) programs in infants. In 2019, the Swiss National Immunization Technical Advisory Group (NITAG) decided to start evaluating the introduction of universal varicella vaccination. There is a theoretical concern that suboptimal vaccination coverage could lead to a shift in the varicella incidence to older age groups, thereby potentially increasing complication rates. To achieve a high vaccination coverage rate, it is important that practicing physicians comply with a potential recommendation for UVV. We studied the perception of varicella and the current vaccination behavior among Swiss pediatricians and general practitioners (GPs) who treat children. We also assessed their intention to advise parents to vaccinate their children against varicella in the event the Swiss NITAG will recommend UVV. Primary data was collected through a structured, 20-min online survey with Swiss pediatricians and GPs who treat children. 150 physicians participated in the study: 40 GPs in the German-speaking part, 20 GPs in the French-speaking part, 67 pediatricians in the German-speaking part, and 23 pediatricians in the French-speaking part. The majority (64%) of all participants reported that they currently recommend varicella vaccination for risk groups according to the national immunization plan. About one third of physicians (35%) - predominantly pediatricians - currently already recommend it for all infants. In these situations, a measles, mumps, rubella, varicella combination vaccine is currently used by 58% for the first dose and by 59% for the second dose. 86% of participants stated that they would advise parents to have their children vaccinated against varicella in case of a recommendation for UVV by the Swiss NITAG. 68% responded that they expect many questions from parents and 65% agreed that they have good arguments to convey the importance of varicella vaccination. The survey study results show that most participating pediatricians and GPs indicated a favorable attitude towards childhood vaccination against varicella in the setting of a Swiss NITAG recommendation for UVV. This data shows the importance of NITAG recommendations in influencing vaccine education and supporting achievement of high coverage of varicella vaccination.

Sections du résumé

BACKGROUND BACKGROUND
Over the last two decades, several countries have initiated universal varicella vaccination (UVV) programs in infants. In 2019, the Swiss National Immunization Technical Advisory Group (NITAG) decided to start evaluating the introduction of universal varicella vaccination. There is a theoretical concern that suboptimal vaccination coverage could lead to a shift in the varicella incidence to older age groups, thereby potentially increasing complication rates. To achieve a high vaccination coverage rate, it is important that practicing physicians comply with a potential recommendation for UVV. We studied the perception of varicella and the current vaccination behavior among Swiss pediatricians and general practitioners (GPs) who treat children. We also assessed their intention to advise parents to vaccinate their children against varicella in the event the Swiss NITAG will recommend UVV.
METHODS METHODS
Primary data was collected through a structured, 20-min online survey with Swiss pediatricians and GPs who treat children.
RESULTS RESULTS
150 physicians participated in the study: 40 GPs in the German-speaking part, 20 GPs in the French-speaking part, 67 pediatricians in the German-speaking part, and 23 pediatricians in the French-speaking part. The majority (64%) of all participants reported that they currently recommend varicella vaccination for risk groups according to the national immunization plan. About one third of physicians (35%) - predominantly pediatricians - currently already recommend it for all infants. In these situations, a measles, mumps, rubella, varicella combination vaccine is currently used by 58% for the first dose and by 59% for the second dose. 86% of participants stated that they would advise parents to have their children vaccinated against varicella in case of a recommendation for UVV by the Swiss NITAG. 68% responded that they expect many questions from parents and 65% agreed that they have good arguments to convey the importance of varicella vaccination.
CONCLUSIONS CONCLUSIONS
The survey study results show that most participating pediatricians and GPs indicated a favorable attitude towards childhood vaccination against varicella in the setting of a Swiss NITAG recommendation for UVV. This data shows the importance of NITAG recommendations in influencing vaccine education and supporting achievement of high coverage of varicella vaccination.

Identifiants

pubmed: 33407202
doi: 10.1186/s12879-020-05586-3
pii: 10.1186/s12879-020-05586-3
pmc: PMC7789518
doi:

Substances chimiques

Chickenpox Vaccine 0
Vaccines, Combined 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

12

Références

Vaccine. 2014 Jan 3;32(2):277-83
pubmed: 24275483
Epidemiol Infect. 2017 Oct;145(13):2666-2677
pubmed: 28826422
BMC Infect Dis. 2017 Feb 27;17(1):172
pubmed: 28241788
J Paediatr Child Health. 2018 Jan;54(1):28-35
pubmed: 28795455
Vaccine. 2016 Dec 20;34(52):6700-6706
pubmed: 27810314
Pediatr Infect Dis J. 2019 Feb;38(2):181-188
pubmed: 30408002
J Pediatr. 2016 Oct;177S:S203-S212
pubmed: 27666268
BMC Infect Dis. 2016 Mar 15;16:127
pubmed: 26979822
Eur J Pediatr. 2005 Jun;164(6):366-70
pubmed: 15747132
Clin Microbiol Rev. 1996 Jul;9(3):361-81
pubmed: 8809466
Lancet. 2006 Oct 14;368(9544):1365-76
pubmed: 17046469
Hum Vaccin Immunother. 2014;10(12):3594-600
pubmed: 25483695
Vaccine. 2006 Sep 11;24(37-39):6351-5
pubmed: 16784799
Hum Vaccin Immunother. 2015;11(1):63-71
pubmed: 25483517
Hum Vaccin Immunother. 2014;10(2):476-84
pubmed: 24192604
MMWR Morb Mortal Wkly Rep. 2016 Sep 02;65(34):902-5
pubmed: 27584717
Am J Epidemiol. 1994 Jul 15;140(2):81-104
pubmed: 8023813
Hum Vaccin Immunother. 2019;15(3):645-657
pubmed: 30427766
Vaccine. 2011 Mar 16;29(13):2411-20
pubmed: 21277405

Auteurs

Florian Lienert (F)

MSD Merck Sharp & Dohme AG, Lucerne, Switzerland. florian.lienert@gmail.com.
Current affiliation: Bavarian Nordic AG, Zug, Switzerland. florian.lienert@gmail.com.

Olivia Weiss (O)

IPSOS, Basel, Switzerland.

Kathrin Schmitt (K)

IPSOS, Basel, Switzerland.

Ulrich Heininger (U)

Department of Pediatric Infectious Diseases and Vaccinology, University of Basel Children's Hospital, Basel, Switzerland.

Patrik Guggisberg (P)

MSD Merck Sharp & Dohme AG, Lucerne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH